Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-26T19:56:49.314Z Has data issue: false hasContentIssue false

Effect of prospective audit and feedback on inpatient fluoroquinolone use and appropriateness of prescribing

Published online by Cambridge University Press:  07 August 2020

Caitlyn M. Marek
Affiliation:
Division of Infectious Diseases, Department of Medicine, Interior Health, Kamloops, British Columbia, Canada
Karen J. Zurek
Affiliation:
Department of Pharmacy, Covenant Health, Edmonton, Alberta, Canada
Owen Degenhardt
Affiliation:
Department of Pharmacy, Covenant Health, Edmonton, Alberta, Canada
Shahileen Remtulla
Affiliation:
Department of Pharmacy, Covenant Health, Edmonton, Alberta, Canada
Alastair S. Teale
Affiliation:
Division of Infectious Diseases, Department of Medicine, Island Health, Nanaimo, British Columbia, Canada
Carlos Cervera
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Holly L. Hoang*
Affiliation:
Division of Infectious Diseases, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
*
Author for correspondence: Holly Hoang, E-mail: [email protected]

Abstract

We report the effect of prospective audit and feedback (PAF) on inpatient fluoroquinolone (FQN) prescriptions. During the PAF period, FQN use decreased from 39.19 to 29.58 days of therapy per 1,000 patient days (P < .001) and appropriateness improved from 68% to 88% (P < .001). High-yield indications to target included noninfectious urinary tract and respiratory presentations.

Type
Concise Communication
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Recalls and safety alerts. Fluoroquinolones—risk of disabling and persistent serious adverse reactions. Government of Canada website. http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/61900a-eng.php. Published 2017. Accessed May 2019.Google Scholar
2018 drug safety communications. Food and Drug Administration website. https://www.fda.gov/drugs/drug-safety-and-availability/2018-drug-safety-communications. Published 2018. Accessed June 2019.Google Scholar
National antibiogram, 2017. Canadian Antimicrobial Resistance Alliance website. http://can-r.com/study.php?study=antb2017&year=2017. Published 2017. Accessed May 2019.Google Scholar
Werner, NL, Hecker, MT, Sethi, AK, et al. Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis 2011;11:187.CrossRefGoogle ScholarPubMed
Méan, M, Pavese, P, Vittoz, JP, et al. Prospective assessment of fluoroquinolone use in a teaching hospital. Eur J Clin Microbiol Infect Dis 2006; 25:757763.CrossRefGoogle Scholar
Wise, BL, Peloquin, C, Choi, H, et al. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med 2012;125:1228e231228e28.Google ScholarPubMed
Fleming, D, Ali, KF, Matelski, J, et al. When antimicrobial stewardship isn’t watching: the educational impact of critical care prospective audit and feedback. Open Forum Infect Dis 2016;3(3):ofw115.Google ScholarPubMed
Willemsen, I, Cooper, B, van Buitenen, C, et al. Improving quinolone use in hospitals by using a bundle of interventions in an interrupted time series analysis. Antimicrob Agents Chemother 2010;54:37633769.Google Scholar
Wong-Beringer, A, Nguyen, LH, Lee, M, et al. An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse. Pharmacotherapy 2009;29:736743.CrossRefGoogle ScholarPubMed
Vaughn, VM, Gandhi, T, Conlon, A, Chopra, V, et al. The association of antibiotic stewardship with fluoroquinolone prescribing in Michigan hospitals: a multihospital cohort study. Clin Infect Dis 2019;69:12691277.CrossRefGoogle Scholar
Supplementary material: File

Marek et al. supplementary material

Marek et al. supplementary material

Download Marek et al. supplementary material(File)
File 16.6 KB